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Abstract
Background: Fibroblastic foci are characteristic features in lung parenchyma of patients with idiopathic
pulmonary fibrosis (IPF). They comprise aggregates of mesenchymal cells which underlie sites of
unresolved epithelial injury and are associated with progression of fibrosis. However, the cellular origins
of these mesenchymal phenotypes remain unclear. We examined whether the potent fibrogenic cytokine
TGF-β 1 could induce epithelial mesenchymal transition (EMT) in the human alveolar epithelial cell line,
A549, and investigated the signaling pathway of TGF-β 1-mediated EMT.
Methods: A549 cells were examined for evidence of EMT after treatment with TGF-β 1. EMT was
assessed by: morphology under phase-contrast microscopy; Western analysis of cell lysates for expression
of mesenchymal phenotypic markers including fibronectin EDA (Fn-EDA), and expression of epithelial
phenotypic markers including E-cadherin (E-cad). Markers of fibrogenesis, including collagens and
connective tissue growth factor (CTGF) were also evaluated by measuring mRNA level using RT-PCR, and
protein by immunofluorescence or Western blotting. Signaling pathways for EMT were characterized by
Western analysis of cell lysates using monoclonal antibodies to detect phosphorylated Erk1/2 and Smad2
after TGF-β 1 treatment in the presence or absence of MEK inhibitors. The role of Smad2 in TGF-β 1-
mediated EMT was investigated using siRNA.
Results: The data showed that TGF-β 1, but not TNF-α  or IL-1β , induced A549 cells with an alveolar
epithelial type II cell phenotype to undergo EMT in a time-and concentration-dependent manner. The
process of EMT was accompanied by morphological alteration and expression of the fibroblast phenotypic
markers Fn-EDA and vimentin, concomitant with a downregulation of the epithelial phenotype marker E-
cad. Furthermore, cells that had undergone EMT showed enhanced expression of markers of fibrogenesis
including collagens type I and III and CTGF. MMP-2 expression was also evidenced. TGF-β 1-induced EMT
occurred through phosphorylation of Smad2 and was inhibited by Smad2 gene silencing; MEK inhibitors
failed to attenuate either EMT-associated Smad2 phosphorylation or the observed phenotypic changes.
Conclusion: Our study shows that TGF-β 1 induces A549 alveolar epithelial cells to undergo EMT via
Smad2 activation. Our data support the concept of EMT in lung epithelial cells, and suggest the need for
further studies to investigate the phenomenon.
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Background
Idiopathic pulmonary fibrosis (IPF), the most common
pulmonary fibrotic disorder, is a progressive and lethal
disease of unknown etiology whose pathogenesis
uniquely features the presence of fibroblastic foci in the
parenchyma of the lungs [1]. These are comprised of
aggregates of mesenchymal cells including fibroblasts and
cells which exhibit phenotypic features of myofibroblasts,
α -smooth muscle actin (α SMA) expression, increased
mitogenic capacity, and enhanced extracellular matrix
(ECM) production. The number of fibroblastic foci corre-
lates with worsening lung function, progression of IPF
and a poor prognosis [2]. According to the recent epithe-
lial/fibroblastic model of IPF pathogenesis it is considered
that fibroblastic foci underlie areas of unresolved epithe-
lial injury and are sites where activated fibroblasts and
myofibroblasts migrate, proliferate and synthesize ECM
proteins [3]. However, the cellular origins of the mesen-
chymal phenotypes in fibroblast foci remain unclear.
It is now well recognized from many studies that a
number of key growth factors are responsible for driving
the process of fibrogenesis [4]. For example, transforming
growth factor-beta1 (TGF-β 1), interleukin-1 beta (IL-1β ),
and tumor necrosis factor-alpha (TNF-α ) are able to
induce the characteristic motility, proliferation and ECM
synthesis observed in mesenchymal cells with a myofi-
broblast-like phenotype from fibroblastic foci. In general
though, it is levels of TGF-β 1 that best correlate with the
extent of fibrosis and myofibroblast-like cell induction [5]
and TGF-β 1 continues to be regarded as the most impor-
tant of the growth factors involved in pulmonary fibro-
genesis [6]. For example, the biologically active form of
TGF-β 1 was aberrantly expressed in the epithelial cells lin-
ing honeycomb cysts within the lung of patients with IPF
[7,8]. An increased level of TGF-β 1 was found in BAL fluid
derived from patients suffering from IPF [8]. Furthermore,
overexpression of TGF-β 1 in lung tissue induced pro-
longed pulmonary fibrosis in an animal model [9].
Recent evidence from studies of other fibrotic disorders,
including renal [10,11] and liver fibrosis [12], supports a
view that TGF-β 1 may play a novel role in pulmonary
fibrogenesis by promoting alveolar epithelial cell transi-
tion to form mesenchymal cells with a myofibroblast-like
phenotype [10-14]. This process, termed epithelial-mes-
enchymal transition (EMT), occurs widely under both
physiologic and pathologic conditions, for example dur-
ing normal wound healing [13] and renal fibrosis [10,11].
Very recently it was reported that TGF-β 1 induced type II
alveolar epithelial cells isolated from rat lung to undergo
EMT [15]. Epithelial cells are polarised, and display cytok-
eratin filaments and membrane-associated junctions.
During EMT membrane-associated adherens junctions
and desmosomes are dissociated, whilst at the same time
or shortly after, cytoskeletal rearrangement takes place
and mRNA for intermediate filament proteins is
increased, facilitating the cell adopting a mesenchymal
phenotype [14]. E-cadherin (E-cad) is an epithelial cell
transmembrane protein whose extracellular domain inter-
acts with that of an E-cad molecule expressed by an adja-
cent cell. It has a critical role in establishing firm
adhesion, maintaining cell polarity and epithelial tight-
ness [16]. The cadherin complex suppresses the dissocia-
tion of epithelial cells, and thus, the crucial step of EMT is
the downregulation of E-cad [14].
To begin to understand the role of EMT in the develop-
ment of fibroblastic foci in IPF, we have examined
whether TGF-β 1 can induce EMT in a human lung epithe-
lial cell line (A549). A549 cells retain important character-
istics of alveolar type II epithelial cells and have been
employed in numerous studies as a valuable tool for stud-
ying promoter activity [17], apoptosis [18], and alveolar
epithelial cell DNA damage [19]. In this study we demon-
strate that TGF-β 1 induces EMT in human type II alveolar
epithelial cells through the activation of Smad2, and that
this transition is accompanied by functional changes that
are relevant to the progression of lung fibrosis.
Methods
Materials
Recombinant human TGF-β 1, human IL-1β ; and TNF-α
were purchased from R&D systems (Minneapolis, MN). A
mouse monoclonal antibody against human E-cad was
from BD Transduction Laboratory (Oxford, UK). Mouse
monoclonal anti-human fibronectin EDA+  splice form
(Fn-EDA) and anti-human cytokeratin-19 were purchased
from Abcam Ltd (Cambridge, UK). Goat anti-actin (C-
11), Smad2 (S-20) and connective tissue growth factor
(CTGF) polyclonal antibodies were supplied by Santa
Cruz Biotechnology (Santa Cruz, CA). Rabbit anti-Erk1/2
and rabbit anti-phosphorylated Erk1/2 polyclonal anti-
bodies were purchased from New England Biolabs (Hert-
fordshire, UK). Both biotinylated and non-biotinylated
goat anti-human collagen type I, type III, and type IV pol-
yclonal antibodies, and their standard proteins were sup-
plied by Chemicon International (Temecula, CA). Rabbit
anti-mouse immunoglobulin-HRP, rabbit anti-goat
immunoglobulin-HRP and goat anti-rabbit immunoglob-
ulin HRP were from DAKO Ltd (Cambridgeshire, UK).
Rabbit anti-goat IgG-fluorescein (FITC) was purchased
from Vector Labs (Perterborough, UK). Alkaline phos-
phatase-conjugated anti-Extravidin was supplied by
Sigma (Dorset, Poole). PD-098059 and U-0126 were sup-
plied by Merck Bioscience Ltd (Nottingham, UK). SMART-
pool SMAD2 and non-specific control pool were
purchased from Dharmacon, Inc. (Chicago, IL).Respiratory Research 2005, 6:56 http://respiratory-research.com/content/6/1/56
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Cell culture
Human type II alveolar epithelial cells (A549) were sup-
plied from ATCC/LGC Promochem (Middlesex, UK).
Cells were maintained in low glucose-DMEM containing
10% FBS, 2 mM L-glutamine, 100 U/ml penicillin and
100 ug/ml streptomycin at 37°C in a humidified 5% CO2
atmosphere. Confluent cultures of cells were maintained
in serum-free DMEM containing 0.1% BSA for 24 h prior
to stimulation with cytokines. The cells were incubated
with several concentrations of the cytokines for the peri-
ods indicated. In experiments using inhibitors of MAPK/
Erk kinase (MEK), the cells were preincubated for 1 h with
PD-098059 or U-0126 (up to 10 µM) before treatment
with exogenous TGF-β 1. In small interfering RNA
(siRNA)-dependent gene silencing experiments, after
transfection the cells were stimulated with 5 ng/ml of
TGF-β 1 in serum free 0.1% BSA/DMEM for 48 h. The cells
were then harvested and lysed. In experiments testing col-
lagen expression, the cells were incubated in the presence
of 5 ug/ml of L-ascorbic acid. For immunocytochemical
staining, the cells were maintained throughout the exper-
iment in culture medium without serum deprivation.
SDS-PAGE and Western blot
The cells were scraped and lysed in M-PER (Pierce, Chesh-
ire, UK) containing a protease inhibitor cocktail (Roche
Diagnostic, East Sussex, UK). Cell suspensions were
cleared by centrifugation at 13,000 g for 15 min at 4°C.
Total protein concentration was measured using the BCA
protein assay kit (Pierce) with bovine serum albumin as
the standard protein. Equal amounts of protein were
loaded for each lane of 10% SDS PAGE gels, followed by
electrophoresis, and protein transfers to Hybond ECL
membranes (Amersham, Buckinghamshire, UK), as
described previously [14]. After the transfer, membranes
were blocked with 5% skimmed milk and then probed
with primary antibodies for 1 h at room temperature.
After washing, the membranes were probed with appro-
priate peroxidase-conjugated secondary antibodies. After
further extensive washing, the immunoblots were visual-
ized by ECL (Amersham) and the band densities for each
phenotype marker were quantified using QuantityOne
Software (Bio-Rad) after scanning with a GS-710 Cali-
brated Imaging Densitometer (Bio-Rad). Results were
expressed as a ratio of band density to total actin. For
Western blotting of phosphorylated proteins, the cells
were scraped and lyzed in RIPA buffer containing a pro-
tease inhibitor cocktail (Roche), plus 1 mM sodium-
orthovanadate and 1 mM NaF. Western blot was per-
formed according to manufacturer's instructions for each
antibody. Changes in levels of phosphorylated proteins
were assessed with reference to the respective non-phos-
phorylated proteins.
Reverse Transcription PCR (RT-PCR)
Total RNA was isolated using Trizol (Invitrogen, Carlsbad,
CA). A one-step RT-PCR was performed using the Super-
Script One-Step RT-PCR kit (Invitrogen). The target tran-
script was reverse transcribed at 50°C for 30 min. The PCR
products for type III collagen and GAPDH were amplified
using 35 cycles (initial denaturation at 94°C/2 min fol-
lowed by PCR amplification, 94°C/15 s, 60°C/30 s, and
68°C/1 min). For type I collagen, the PCR product was
amplified using 35 cycles (initial denaturation at 94°C/2
min followed by PCR amplification, 94°C/30 s, 58°C/30
s, and 68°C/1 min). PCR products were visualized on a
GelDoc 1000 system (Bio-Rad) and semi-quantified using
a scanning densitometer. The following primers were used
for amplification of target transcripts; human collagen
type I forward; 5'-ACGTCCTGGTGAAGTTGGTC-3',
human collagen type I reverse; 5'-ACCAG-
GGAAGCCTCTCTCTC-3', human collagen type III for-
ward; 5'-AGCCTCATTAGTCCTGATGGTTCTCG-3',
human collagen type III reverse; 5'-CTTCTCAGCACTA-
GAATCTGTCCACC-3', human GAPDH forward; 5'-
GGGCTGCTTTTAACTCTGGT-3', human GAPDH reverse;
5'-TGGCAGGTTTTTCTAGACGG-3'.
RNA Interference and Transfection
Dharmacon's SMARTpool SMAD2 siRNA reagent
includes a pool of 4 SMARTselection-designed synthetic
Smad2 siRNA duplexes, together with a non-specific con-
trol pool of siRNA as a negative control. Transfection of
these pooled 21-nucleotide siRNA duplexes was carried
out using Lipofectamine 2000 (Invitrogen), following the
manufacturer's instructions. Cells were seeded at 5 × 104
cells/well of 24 wells plate and then incubated in normal
medium without antibiotics for overnight to reach 80–
90% confluence. siRNA-transfection reagent complexes
were prepared as described by the manufacturer. Briefly 1
µl/well Lipofectamine 2000 was mixed with either 50
pmol/well Smad2 or negative control siRNA. FITC conju-
gated dsRNA (Block-iT, Invitrogen) was used as positive
control. The cells were then transfected with siRNA/Lipo-
fectamine complexes in Opti-MEM (Invitrogen) and incu-
bated for 24 h at 37°C in a CO2 incubator. Following
incubation, transfection efficiency was evaluated under
fluorescence microscopy.
Immunocytochemistry
Cells were plated into a Lab-TeK Chamber Slide at a den-
sity of 2 × 104 cells/well and grown until approximately
80% confluent, after which they were treated with TGF-β 1
at 5 ng/ml for 72 h, as described above. The cells were
washed, fixed in ice-cold methanol for 10 min, and then
soaked in PBS containing 2% TritonX-100 for 5 min to
increase their permeability to antibodies. These cells were
exposed to antibodies (1:20) for 1 h. After washing,
bound primary antibodies were detected usingRespiratory Research 2005, 6:56 http://respiratory-research.com/content/6/1/56
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appropriate FITC-conjugated secondary antibodies
(1:50). Images were collected using an Eclipse TE2000-S
microscope system (Nikon UK Ltd, Surrey) and Image-Pro
Plus (Media Cybernetics UK, Berkshire).
Gelatin zymography for matrix metalloproteinases 
(MMPs) expression
Conditioned media were concentrated approximately 10-
fold using ultra-centrifugation. After measuring protein
concentration, equal amounts of samples were mixed
with an equal volume of 2 × non-reducing SDS PAGE
sample buffer. The samples were applied to a 10% (w/v)
polyacrylamide gel impregnated with 2 mg/ml gelatin
(Sigma). After electrophoresis, SDS was removed from the
gel by washing 3 times for 10 min in 2.5% Triton X-100
solution. Then the gels were incubated overnight with
gentle shaking at 37°C in buffer (50 mM Tris-HCl
(pH7.6), 10 mM CaCl2, 50 mM NaCl, 0.05% Brij35),
after which, the gel was stained with 0.25% Coomassie
blue R250 in 40% methanol and 10% acetic acid for 2 h
at room temperature, and subsequently destained with a
40% methanol-10% acetic acid solution until the bands
became clear.
ELISA
Culture media were analyzed for collagens type I, type III
and type IV using sandwich ELISA [14]. Each purified
human collagen was used as a standard. Culture media
were incubated in ELISA plates in which wells had been
coated with non-biotinylated primary antibodies. Follow-
ing addition of biotinylated antibodies, the plates were
washed and reacted with alkaline phosphatase-conju-
gated anti-Extravidin. P-nitrophenyl phosphate substrate
tablets were used to detect alkaline phosphatase activity
and the product was measured at 405 nm using a micro-
plate reader (Bio-Rad).
Statistical analysis
Data are presented as the mean ± SD of at least three inde-
pendent experiments. For statistical analysis, an unpaired
t-test was used for pair-wise comparisons and ANOVA
with Dunnett's post test for other data. Statistical analysis
was performed using commercial statistical software
Prism Version 4.0 (GraphPad, Software Inc., San Diego,
CA). P values less than 0.05 were considered as statisti-
cally significant.
Results
TGF-β 1 induces alveolar epithelial cells to undergo EMT
We first determined the optimum concentrations and
time required for TGF-β 1 to initiate EMT in cultures of the
alveolar type II epithelial cell line, A549. The expression of
the epithelial phenotype markers, E-cad and cytokeratin
19, and of the mesenchymal phenotype markers, Fn-EDA
and vimentin, were determined following treatment of
A549 cells with various concentrations (0.01–10 ng/ml)
of TGF-β 1 for 24, 48 and 72 h (Figure 1). Changes in cell
morphology were also assessed under phase contrast light
microscopy (Figure 2).
TGF-β 1 significantly (P < 0.01) decreased E-cad expres-
sion in a concentration-and time-dependent manner (Fig-
ure 1A). Concentrations as low as 1 ng/ml of TGF-β 1
induced up to 70% loss of E-cad expression within 48 h
(Figure 1B). However, the extent of cytokeration 19 sup-
pression was not as profound as for E-cad. Only high con-
centrations of TGF-β 1 resulted in a measurable decrease
(Figure 1B). In parallel with the marked decrease in the E-
cad epithelial marker, TGF-β 1 significantly (P < 0.01)
induced expression of the mesenchymal marker Fn-EDA,
in a concentration-and time-dependent manner (Figure
1A). But the level of vimentin expression was not as pro-
found as for Fn-EDA. Our data also suggested that the de
novo expression of Fn-EDA might occur earlier than E-cad
suppression (Figure 1A).
In addition to the changes in the phenotypic markers
expressed in A549 cells after TGF-β 1 stimulation, the cells
also underwent morphological changes on exposure to
the growth factor (Figure 2). A549 cells cultured in the
absence of TGF-β 1 maintained a classic cobblestone epi-
thelial morphology and growth pattern (Figure 2A), but
after stimulation with 5 ng/ml of TGF-β 1 for 48 h, the cells
adopted a more fibroblast-like morphology and reduced
their cell-cell contact (Figure 2B).
Both IL-1β  and TNF-α  have been suggested to play a role
in fibroblast/myofibroblast motility, proliferation and
ECM synthesis [4], and IL-1β  induces kidney epithelial
cells to undergo EMT [20,21]. We therefore tested whether
these cytokines had similar properties to TGF-β 1 in induc-
ing lung alveolar epithelial cells to form mesenchymal-
like cells. Up to 20 ng/ml of IL-1β  had no effect on the
expression of any of the molecular markers examined,
whilst TNF-α , at 20 ng/ml concentration, resulted in a
~20% fall in the expression of E-cad (Figure 3). Neither
TNF-α  nor IL-1β  induced the expression of Fn-EDA. These
results suggested that alveolar EMT might be induced by
aberrant expression and activation of TGF-β 1 rather than
by IL-1β  or TNF-α .
TGF-β 1-induced EMT is accompanied by other changes 
relevant to fibrogenesis
The results presented above suggest that lung epithelial
cells take on a mesenchymal-like phenotype in response
to TGF-β 1. To confirm this, we examined the expression of
collagen type I and type III by A549 cells in the presence
and absence of TGF-β 1, as these fibrillar collagens are
characteristically synthesized by fibroblastic-type cells.
We compared the production of these fibrillar collagensRespiratory Research 2005, 6:56 http://respiratory-research.com/content/6/1/56
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Expression changes of EMT-related markers in A549 cells Figure 1
Expression changes of EMT-related markers in A549 cells. (A) A549 cells were incubated with up to 10 ng/ml of TGF-
β 1 in the absence of serum for up to 72 h. Expression of the epithelial marker E-cadherin is down-regulated by TGF-β 1 stimu-
lation in a concentration-and time-dependent manner. Expression of Fn-EDA, which is a mesenchymal marker, is up-regulated 
by TGF-β 1 in parallel with the down regulation in the epithelial marker. The same amounts of total protein are loaded in each 
lane. (B) Densitometric analysis of band intensities for each EMT related marker was performed at 48 h. Each bar represents 
mean ± SD of three independent experiments. * P < 0.05 and ** P < 0.01.
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with that of type IV collagen which is characteristically
synthesized by epithelial cells making basement mem-
brane. Cells were treated with several concentrations of
TGF-β 1, and the effects on collagen expression assessed by
RT-PCR; protein synthesis of collagens was also examined
by ELISA and immunocytochemical staining. Figure 4
shows that TGF-β 1 significantly (P < 0.01) stimulated the
expression of collagens type I and type III, as detected by
both RT-PCR (Figure 4A) and immuno-staining of the cell
layer (Figure 4B). Protein levels of collagens type I and
type III secreted into the culture medium were too low to
be measured quantitatively by ELISA. Interestingly, the
secretion of collagen type IV into the medium was
increased in the presence of TGF-β 1 (Figure 5). Concen-
trations of TGF-β 1 as low as 0.1 ng/ml significantly
induced secretion of collagen type IV as compared with
control cells, the increased secretion level reaching a pla-
teau at 1 ng/ml of TGF-β 1 (Figure 5).
CTGF acts in concert with TGF-β 1 and is thought to have
a significant role in promoting and maintaining fibrogen-
esis [22]. Thus, we investigated whether the expression of
CTGF in A549 was affected by TGF-β 1 treatment. Western
analysis of both A549 cell lysates (Figure 6) and culture
medium (data not shown) indicated that treatment with
TGF-β 1 at concentrations >1 ng/ml upregulated the
expression of native CTGF (36–38 kDa) in a time-depend-
ent manner. An additional smaller immunoreactive CTGF
species was also detected and may correspond to a CTGF
breakdown product which is frequently found in cell cul-
tures [23].
MMPs expression was examined using gelatin zymogra-
phy to check whether A549 cells adopt characteristics nec-
essary for cell migration in response to TGF-β 1 treatment.
As shown in Figure 7, A549 cells express gelatinases with
molecular weights consistent with an identity of MMP-2
and MMP-9. MMP-2 was the main gelatinase expressed
and TGF-β 1 treatment up-regulated MMP-2 expression in
a concentration-dependent manner. Basal MMP-9 expres-
sion was low and TGF-β 1 had almost no effect on it.
EMT is associated with TGF-β 1 signalling through the 
Smad pathway rather than via MAP Kinases
TGF-β 1 signaling involves both the Smads and MAP
kinases pathways [24]. The phosphorylation of Erk1/2
and Smad2 was examined at various time points after add-
ing TGF-β 1 (5 ng/ml) to A549 cells. The phosphorylation
of Erk1/2 was increased slightly at 5 min after stimulation,
and this effect lasted for at least 4 h without alteration of
total Erk1/2 protein (Figure 8A). The TGF-β 1-induced
phosphorylation of Erk1/2 was completely suppressed in
the presence of the MEK inhibitors, PD98059 (data not
shown) or U0126 (Figure 8A). However MEK inhibitors
had little or no effect on TGFβ 1-induced changes in the
expression of EMT markers over 48 h (Figure 8B).
Interestingly, 5 ng/ml of TGF-β 1 induced phosphoryla-
tion of Smad2 within 5 min of stimulation, and the level
of Smad2 phosphorylation reached a maximum between
30–60 min after treatment and remained elevated for the
duration of the experiment without affecting total Smad2
expression (Figure 8A). Co-incubation with either of the
MEK inhibitors, PD98059 (data not shown) or U0126,
had no effect on the TGF-β 1 mediated Smad2 phosphor-
ylation (Figure 8A). Taken together, these data indicate
that rapid and sustained phosphorylation of Smad2 is
associated with TGF-β 1-induced EMT events and that
TGF-β 1-induced Erk1/2 signalling pathways are less likely
to be involved in the EMT of A549 cells.
Morphological changes induced by TGF-β 1 Figure 2
Morphological changes induced by TGF-β 1. A549 cells 
were incubated with 5 ng/ml of TGF-β 1 for 48 h. (A) 
Untreated A549 cells show a pebble-like shape and cell-cell 
adhesion is clearly observed. (B) TGF-β 1-treated cells show a 
decrease in cell-cell contacts and adopt a more elongated 
morphological shape (magnification of 200×).
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siRNA-mediated Smad2 gene silencing inhibits TGF-β -
mediated EMT
In order to confirm whether Smad2 is involved in TGF-β 1-
mediated EMT, siRNAs were used to silence Smad2 gene
expression in A549 cells. Transfection efficiency, using
FITC-conjugated dsRNA oligomers, was approximately
100 % (data not shown). Western analysis revealed that
total Smad2 protein expression was significantly (P <
0.01) depleted by Smad2 siRNA gene silencing, while
pooled negative control siRNA had no detectable effect on
Smad2 protein expression (Figure 9). Using a phospho-
specific antibody against Smad2, we also tested for the
effect of Smad2 siRNA on phosphorylated Smad2 levels
after TGF-β 1 treatment. In the presence of TGF-β 1 phos-
phorylated Smad2 levels were significantly (P < 0.01)
diminished by Smad2 siRNA (Figure 9). Most impor-
tantly, Smad2 siRNA restored the decreased expression of
E-cad and cytokeration 19 induced by TGF-β 1 treatment.
However, the expression of Fn-EDA and vimentin were
only slightly suppressed by Smad2 siRNA (Figure 9). Nev-
ertheless, our data suggest that the activation of Smad2
signaling pathway is involved in TGF-β 1-mediated EMT in
A549 cells.
Discussion
Fibroblastic foci in the IPF lung parenchyma are character-
ized by vigorous replication of mesenchymal cells, includ-
ing fibroblasts and myofibroblasts, and subsequent
abnormal deposition of ECM proteins [25]. However, pre-
cise mechanisms responsible for the formation of fibrob-
lastic foci are unknown and their cellular origins are
unclear. It is recognized though, that injury to the alveolar
epithelium precedes their formation and that epithelial
cells may therefore contribute to their formation, perhaps
by their responses to, or production of, key fibrogenic
mediators including TGF-β 1 [3]. Thus, one possible role
of TGF-β 1 in IPF is to induce or promote epithelial cells in
injured alveolar epithelium to undergo EMT [15], as is evi-
dent from studies of other fibrotic disorders such as renal
fibrosis [10,11,14]. Cells that have undergone EMT would
then contribute to the development of fibroblastic foci
and to their abnormal ECM production. The results of our
present in vitro study support the concept underpinning
this hypothesis; namely that TGF-β 1 can induce alveolar
EMT in human lung epithelial cells via the Smad2
pathway.
Comparison of EMT-related marker expression in response to TGF-β 1, IL-1β  and TNF-α  treatments Figure 3
Comparison of EMT-related marker expression in response to TGF-β 1, IL-1β  and TNF-α  treatments. A549 cells 
were incubated with TGF-β 1, IL-1β  and TNF-α  at the indicated concentrations for 48 h. Only TGF-β 1 decreases E-cadherin 
expression concomitant with increasing Fn-EDA expression. In contrast, TNF-α  only slightly decreases E-cadherin expression 
and IL-1β  has no influence on EMT-related marker expression. Equal amounts of total protein are loaded in each lane.
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TGF-β 1 induces the expression of collagens type I and type III Figure 4
TGF-β 1 induces the expression of collagens type I and type III. A549 cells were incubated with 5 ng/ml of TGF-β 1 in 
the presence of 5 µg/ml of L-ascorbic acid for 72 h. (A) mRNA expression of collagens type I and type III was detected using 
RT-PCR. Densitometric analysis was performed. The changes of expression level are expressed as fold increase compared to 
the control. Each bar represents the mean ± SD of three independent experiments. ** P < 0.01. (B) Protein expression of col-
lagens type I and type III was detected by immunocytochemical staining. Panels (a) and (b) represent collagen type I and panels 
(c) and (d) represent collagen type III expression, respectively. TGF-β 1 induces collagen type I and type III expression in A549 
as shown in panel (b) and (d).
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Epithelial phenotype is determined by the specific range
of proteins expressed by the epithelial cell and the nature
of its environment [14,26,27]. E-cad is an epithelial cell
transmembrane protein with conserved cadherin repeats
in the extracellular domain. In the presence of Ca2+, the
extracellular domain binds to that of E-cad on an adjacent
epithelial cell to form tight cell-cell adhesion and to sup-
press the dissociation of epithelial cells from their
location. Certain morphogenic and/or environmental
cues, such as local expression of TGF-β 1, result in the loss
of epithelial cell polarity, adherens junctions, tight junc-
tions, desmosomes, cytokeratin intermediate filaments
and, subsequently, rearrangement of F-actin stress fibers
and the development of filopodia and lamelopodia
[10,11]. Several in vitro studies have demonstrated that
addition of TGF-β 1 to cultured human epithelial cells
from organs other than lung induces them to
downregulate E-cad expression and to become mesenchy-
mal cells, resembling myofibroblasts, via EMT [27-29].
In the present study, we investigated the potential for alve-
olar EMT by examining the expression of phenotypic
markers in A549 cells. Although submerged monolayer
culture of A549 may not completely mimic the pulmo-
nary epithelium, these cells are still widely used for studies
on the role of human alveolar type II epithelial cells as
they retain features and metabolic properties characteris-
tic of type II cells [17,19,30]. The present study
demonstrates that low doses of TGF-β 1 induce A549 cells
to lose expression of epithelial phenotypic markers, such
TGF-β 1 increases collagen type IV secretion in A549 Figure 5
TGF-β 1 increases collagen type IV secretion in A549. A549 cells were incubated with several concentrations of TGF-β 1 
in the presence of 5 µg/ml of L-ascorbic acid for 72 h. Concentrations of collagen type IV in conditioned media were deter-
mined using ELISA. TGF-β 1 increases collagen type IV in a concentration-dependent manner. Each bar was expressed as the 
mean ± SD of four independent experiments. ** P < 0.01.
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as E-cad and cytokeratin 19 expression, similar to our pre-
viously reported findings in kidney epithelial EMT [14].
Concurrently A549 cells gain a mesenchymal phenotype
with de novo expression of Fn-EDA and increased expres-
sion of vimentin. In addition to these classic mesenchy-
mal markers, these newly formed mesenchymal cells
expressed the fibrillar collagens type I and type III which
are likely to contribute to excessive accumulation of ECM
in fibrotic tissue. Moreover, these cells expressed an ele-
vated level of MMP-2 after EMT which could contribute to
breakdown of basement membranes and facilitate migra-
tion. Our data is consistent with the findings made in in
kidney tubular epithelial cells where MMP-2 and MMP-9
were up-regulated by TGF-β 1 in parallel with changes in
EMT markers [27,31]. It remains uncertain whether these
fibroblast-like cells possess migratory and/or invasive
capabilities, but TGF-β 1 induced MMP-2 expression in
A549 supports this notion. Clearly further investigation of
cell migration in TGF-β 1-mediated alveolar EMT in lung
fibrosis is warranted.
We have yet to confirm our results in primary human type
II alveolar epithelial cells because cultures of these cells
rapidly adopt fibroblast-like morphology, even in the
absence of TGF-β 1. Therefore, we cannot rule out at this
stage the possibility that the responses of A549 cells to
TGF-β 1 are unique to this human cell line. However, a
recent report indicates that rat primary type II alveolar
epithelial cells undergo EMT in vitro in response to treat-
ment of TGF-β 1 [15], suggesting EMT is likely to be a phe-
nomenon common to all type II alveolar epithelial cells.
In addition to TGF-β 1, many other cytokines, including
IL-1β  and TNF-α , have been suggested to play a role in IPF
[4]. We examined whether, like TGF-β 1, IL-1β  and TNF-α
also convert A549 to fibroblast-like cells. It is widely
accepted that IL-1β  induces EMT of renal epithelial cells
through a TGF-β 1-dependent mechanism [20,21]. How-
ever, our results showed that both TNFα  and IL-1β  failed
to induce alveolar epithelial cells to undergo EMT, possi-
bly due to the differences in the cell types investigated.
Similarly A549 cells failed to respond to stimulation with
30% (v/v) activated PBMC-conditioned medium
TGF-β 1 induces CTGF expression in A549 Figure 6
TGF-β 1 induces CTGF expression in A549. A549 cells were incubated for the times indicated with the concentrations of 
TGF-β 1 shown. Cell lysates were used as a source for Western blot analysis of CTGF expression. Up-regulation of CTGF 
expression is observed with 1 ng/ml and higher concentrations of TGF-β 1. This phenomenon parallels the altered expression 
of EMT related markers. Representative blots are shown from three independent experiments.
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(aPBMC-CM) (H. Kasai, unpublished data), a stimulus
which induces renal epithelial cells to undergo EMT-
mediated conversion to myofibroblasts [14,32,33].
We observed that A549 EMT was not accompanied by
expression of α SMA, even during longer periods (7 days)
of exposure to TGF-β 1 (data not shown). Although α SMA,
together with vimentin and desmin, is often used to clas-
sify myofibroblasts [34,35], the expression of these cellu-
lar markers is varied and dependent on cell types and
culture conditions [36].
TGF-β 1 regulates various cell functions, such as cell prolif-
eration, cell differentiation, apoptosis, cell adhesion/
motility, ECM production, and its association with
pulmonary fibrosis is well known [37]. In vivo studies
have demonstrated increased TGF-β 1 gene expression and
protein secretion in the lungs of animals [38] and humans
with fibrotic diseases [7,8,39]. Furthermore, transient
overexpression of active TGF-β 1 in rat lung resulted in
severe interstitial and pleural fibrosis characterized by
extensive deposition of ECM proteins, and by the emer-
gence of cells with the myofibroblast phenotype [9]. A
time-dependent production of endogenous TGF-β 1 from
rat alveolar epithelial cells after exogenous TGF-β 1 treat-
ment was also noted by Yao et al [15], suggesting initial
EMT induced by TGF-β 1 may result in further EMT
induced by endogenous TGF-β 1 production in an auto-
crine or paracrine manner. Based on these studies and our
data it is tempting to speculate about a role for TGF-β 1-
mediated EMT in pulmonary fibrogenesis. Indirectly, our
data showing TGF-β 1-mediated induction of collagen
type I and type III expression, which are present in fibrotic
lesions in vivo [40], and the expression of Fn-EDA and
vimentin which represent cellular markers for myofibrob-
lasts, supports such a role for EMT.
TGF-β 1 exerts its effects through heteromeric receptor
complexes composed of type I and type II serine/threo-
nine receptors. Upon ligand binding, the type II receptor
phosphorylates the type I receptor inducing its kinase
activity [41]. TGF-β 1 activity may be transduced along the
Smads pathway immediately downstream of the receptor
complex in a variety of cell systems and also via JNK, p38
MAPK and Erk pathways [37,41,42]. Thus, we examined
the intracellular signalling pathway involved in TGF-β 1-
mediated alveolar EMT. Although phosphorylation and
activation of p38 MAPK and Erk1/2 were observed in
some lung fibroblasts [43], our data suggested that the sig-
nalling pathway involved in alveolar EMT was likely to be
a Smad2-dependent pathway since the MEK inhibitors,
PD98059 and U0126, failed to reverse TGF-β 1-induced
phenotypic modulation of A549 cells, whereas Smad2
siRNA attenuated the loss of E-cad and cytokeratin 19
induced by TGF-β 1. Smad2 phosphorylation has been
Effect of TGF-β 1 on MMPs expression in A549 Figure 7
Effect of TGF-β 1 on MMPs expression in A549. Gelatin zymography was performed using the conditioned media that 
were harvested after 48 h TGF-β 1 treatment (0.1 to 5 ng/ml). The samples were applied without reduction to a 10% polyacry-
lamide gel containing gelatin, and proteolytic activity was demonstrated by digestion of the gelatin and clearing of the gel.
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noted in EMT processes for several cell types including
breast and renal epithelial cells [44-46].
Transition from the alveolar epithelial phenotype to the
mesenchymal phenotype initiated by TGF-β 1 was accom-
panied by elevated expression of CTGF. CTGF induction is
mediated through a TGF-β 1 response element in the
CTGF promoter and its mediation of at least some of the
activities attributed to TGF-β 1 is well recognized [4,22], as
is its involvement in the maintenance of fibrogenesis. In
lung for example, Allen et al reported that the mRNA level
of CTGF in BALF cells of patients with IPF was signifi-
cantly higher than that in healthy control subjects [46].
Furthermore, expression of CTGF was found in both
interstitial fibroblasts and type II alveolar epithelial cells
in patients with IPF [47]. CTGF secreted by alveolar epi-
thelial cells and myofibroblasts responding to TGF-β 1
may also act as a paracrine factor for lung fibroblasts and
is known to be a critical intermediate for the synthesis of
connective tissue proteins stimulated by TGF-β 1, but not
by other fibrogenic cytokines [48,49]. CTGF may
therefore play a role in mediating the expression of colla-
Activation of Smad and ERK1/2 pathways by TGF-β 1 Figure 8
Activation of Smad and ERK1/2 pathways by TGF-β 1. A549 cells were pre-incubated in the presence or the absence of 
10 µM of U0126, a potent MEK inhibitor, for 1 h prior to TGF-β 1 stimulation. 5 ng/ml of TGF-β 1 was used as a stimulus. TGF-
β 1 activates Erk1/2 and Smad2 pathways within 5 min after stimulation. The MEK inhibitor blocks Erk1/2 phosphorylation, but 
does not influence Smad2 phosphorylation. Equal amounts of total protein are loaded in each lane.
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gens by EMT cells. Most recently, investigations with
mesangial cells showed that CTGF interacts with the TrkA
receptor, triggering events which lead to the induction of
a transcriptional repressor, TIEG [50]. It was proposed
that since this suppresses negative regulation of the TGF-
β -Smad signaling pathway by repressing Smad7 expres-
sion, it leads to enhanced TGF-β 1 signaling [51]. It is pres-
ently unclear whether CTGF plays a similar role in
alveolar epithelial responses to TGF-β 1, or in EMT cells
derived from them. However, in spite of uncertainties sur-
rounding its precise role, CTGF remains implicated in the
pathogenesis of many fibrotic disorders [4], and is likely
to contribute significantly to fibrogenesis in the lung.
Conclusion
Our findings show that TGF-β 1 induces an EMT-like proc-
ess in A549 alveolar epithelial cells, most likely by activa-
tion of the Smad2 signaling pathway. These data provide
evidence to support the concept that human lung epithe-
lial cells can undergo EMT and indicate a need for further
studies. In particular, the expression profile associated
with alveolar epithelial cells that have undergone EMT
indicates a potential role for EMT in pulmonary
fibrogenesis.
List of abbreviations
IPF = Idiopathic pulmonary fibrosis; α SMA = α -smooth
muscle actin; ECM = extracellular matrix; TGF-β 1 = trans-
Effect of Smad2 siRNA on TGF-β 1 induced EMT in A549 cells Figure 9
Effect of Smad2 siRNA on TGF-β 1 induced EMT in A549 cells. Pooled synthetic siRNA duplexes targeting different 
regions of Smad2 were transfected into A549 cells at 50 pmol per well. 24 h after transfection, cells were stimulated with 5 ng/
ml of TGF-β 1 in serum free 0.1% BSA/DMEM for a further 48 h prior to harvest. Equal amounts of lysates were resolved by 
SDS-PAGE and analyzed by Western blotting for expression of proteins.
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forming growth factor-beta1; IL-1β  = interleukin-1 beta;
TNF-α  = tumor necrosis factor-alpha; EMT = epithelial
mesenchymal transition; E-cad = E-cadherin; Fn-EDA =
fibronectin EDA+ splice form; CTGF = connective tissue
growth factor; MEK = MAPK/Erk kinase; RT-PCR = Reverse
Transcription PCR; MMP = matrix metalloproteinase;
siRNA = small interfering RNA
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